Guidant — Merger or Acquisition (December 2004)
16 slides from Guidant's merger presentation, Dec 16, 2004
Slide 1: All-Employee Briefing on Guidant and Johnson & Johnson Announcement
Filed by Guidant Corporation pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Guidant Corporation Subject Company's Exchange Act File No.: 001-13388 This material is not a substitute for the pros
Slide 2: Slide 2
Slide 3: This material is not a substitute for the prospectus/proxy statement
This material is not a substitute for the prospectus/proxy statement Johnson & Johnson and Guidant (and a subsidiary thereof) will file with the Securities and Exchange Commission. Investors are urged to read the prospectus/proxy statement which will contain important information, including detailed
Slide 4: Today's Announcement
Today’s Announcement Guidant Joins the Johnson & Johnson Family Guidant will become a part of Johnson & Johnson – the largest healthcare company in the world The deal is valued at approximately $23.9 billion based on $76 per share – one of the largest transactions of this year Johnson & Johnson will
Slide 5: Today's Announcement
Today’s Announcement Guidant Joins the Johnson & Johnson Family Ron will postpone his retirement until the deal closes Guidant will be operated consistent with the Johnson & Johnson operating principle of decentralized management, which provides for focused management and fosters an entrepreneurial
Slide 6: Guidant Management Perspective
Guidant Management Perspective “This exciting new partnership opens a dynamic era of innovation and product development that will benefit millions of patients around the world. We are pleased to be joining Johnson & Johnson—one of the world’s premier companies. We strongly believe that this exciting
Slide 7: Johnson & Johnson Management Perspective
Johnson & Johnson Management Perspective “This transaction has the potential to bring innovative new therapies to patients and their physicians for a range of health conditions. Bringing Guidant into the Johnson & Johnson family of companies builds on our history of strategic acquisitions and partne
Slide 8: Rationale for the Agreement
Rationale for the Agreement 1. Complementary strengths and combined resources will allow us to better serve needs of patients and physicians 2. Transaction will result in increased investment to accelerate the development of technologically advanced products 3. Johnson & Johnson’s world-class leader
Slide 9: Complementary Strengths Will Deliver Sustainable Innovation
Complementary Strengths Will Deliver Sustainable Innovation Outstanding people Outstanding people Patient focus Demonstrated success in creating therapy acceptance Technological expertise Public policy expertise Velocity of product innovation Long-term investment focus Clinical science expertise Bro
Slide 10: Employee Opportunity
Employee Opportunity “If one wants to have an interesting career, one needs to be part of an interesting company. I can think of no more interesting company in the healthcare environment than what we are announcing today.” Ron Dollens President and CEO, Guidant 9
Slide 11: Employee Opportunity
Employee Opportunity Guidant and Johnson & Johnson are completely aligned on the future of the combined entity — Johnson & Johnson recognizes and values Guidant’s structure and operating model Guidant’s 12,000 employees have contributed to our position of strength coming into this transaction today
Slide 12: Impact to our Business Model
Impact to our Business Model Johnson & Johnson will combine its expertise in drug coating technology and the manufacturing of drug- eluting stents with Guidant’s expertise in stent design and stent delivery systems Potential to apply Guidant’s technology platforms (e.g. implantable defibrillators an
Slide 13: Who is Johnson & Johnson?
Who is Johnson & Johnson? World’s most comprehensive manufacturer of healthcare products, founded more than 100 years ago Guided by a Credo focused on patients and customers, employees, communities and shareholders 109,000 employees worldwide; 200 operating companies selling in more than 175 countri
Slide 14: Who is Johnson & Johnson?
Who is Johnson & Johnson? Total 2003 Sales: $41.9 Billion Medical Devices & Diagnostics $14.9 Billion 35.6% Consumer 17.8% $7.4 Billion 46.6% Pharmaceuticals $19.5 Billion 13
Slide 15: Economic Considerations
Economic Considerations To assure continuity in operations and enable employees to focus on their jobs… Change in Control Severance Plan: Provides financial security in event of future termination of employment Employees who work 20 hours or more per week are generally eligible Benefits payable afte
Slide 16: Summary
Summary We continue to maintain our focus on our company vision and our day-to-day activities We realize you have many questions – as always, we are committed to open and frequent communications In the weeks ahead, both Guidant and Johnson & Johnson management will be visiting as many sites as possi